Pharmacokinetics and tissue distribution of iv injection of polyphase liposome-encapsulated cisplatin (KM-1) in rats

Acta Pharmacologica Sinica

Volumn 24, Issue 6, 2003, Pages 589-592+623

  Wang, Shan ^a   Mi, Jie Bo ^a   Li, Yuan Zong ^a   Chang, Wen Bao ^a   Ci, Yun Xiang ^a   Zhao, Min Zheng ^b   Zhao, Yun Kun ^b   Zhu, Li Ya ^b   Xu, Guang ^b  

^a PEKING UNIVERSITY   (China)

^b KUNMING INSTITUTE OF PRECIOUS METALS   (China)

Author keywords

Cisplatin; Induced coupled plasma atomic emission spectrometry; Liposomes; Pharmacokinetics

Indexed keywords

CISPLATIN; KM 1; LIPOSOME; PLATINUM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; ATOMIC EMISSION SPECTROMETRY; COMPARTMENT MODEL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; ENCAPSULATION; HEART; KIDNEY; LIVER LEVEL; LUNG; NONHUMAN; RAT; SPLEEN; TESTIS; TISSUE DISTRIBUTION; TISSUE LEVEL;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; DRUG CARRIERS; INJECTIONS, INTRAVENOUS; LIPOSOMES; LIVER; MALE; PLATINUM; RATS; RATS, WISTAR; SPLEEN; TISSUE DISTRIBUTION;

EID: 0037495093     PISSN: 16714083     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Rosenberg b, VanCamp L, Trosko JE, Monsour VH. Platinum compounds: a new class of potent antitumor agents. Nature 1969; 222: 385-6.
2. Einhorn LH, Donohue J. cis-Diaminedichloroplatinum, vinblastine, and bleomycin chemotherapy in disseminated testicular cancer. Ann Intern Med 1977; 87: 293-8.
3. Pearson ADJ, Craft AW, Pinkerton CR, Meller ST, Reid MM. High-dose rapid schedule chemotherapy for disseminated neurolblastoma. Eur J Cancer 1992; 28A: 1654-9.
4. Raymond BW, Michaele CC. New cisplatin analogues in development. Drugs 1993; 46: 360-77.
5. Kelland LR, Clarke SJ, Mckeage MJ. Advances in platinum complex cancer chemotherapy. Platinum Metals Rev 1992; 36: 178-84.
6. Yang YK, Xiong HZ, Pu SP, Liu WP, Chen XZ, He J. Study on the third generation platinum anticancer drugs. Precious Metals 1996; 17: 50-7.
7. Van Hoesel QGCM, Steerenberg PA, Crommelin DJ, Vandijk A, Vanoort W, Klein S, et al. Reduced cardiotoxicity and nephrotoxicity with preservation of antitumor-activity of doxorubicin entrapped in stable liposomes in the LOU/M Ws1 rats. Cancer Res 1984; 44: 3698-705.
8. Herman EH, Rahman A, Ferrans VJ, Vick JA, Schein PS. Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation. Cancer Res 1983; 43: 5427-32.
9. Gabizon A, Catane R, Uziely B. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994; 54: 987-92.
10. Newman MS, Colbern GT, Working PK, Engbers C, Amantea MA. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in longcirculating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol 1999; 43: 1-7.
11. Gondal JA, Preuss HG, Swartz R, Rahman A. Comparative pharmacological, toxicological and antitumoral evaluation of free and liposome-encapsulated cisplatin in rodents. Eur J Cancer 1993; 29A: 1536-42.